Sigma-Aldrich Corporation今天宣布，它已经完成了从Degussa AG获得的ProLigo组（ProMigo）收购。拟议购买的条款未披露。Playigo是一个全球供应商的关键基因组学研究工具，包括用于DNA和RNA合成的自定义DNA，定制RNA和磷酰胺矿石原料，2004年销售额约为4000万美元。亚博网站下载九个月的Provigo的经营结果将在2005年增加西格玛 - Aldrich的表现，将整体销售增长提高约2％。
“正如我们在宣布我们宣布提出此次收购的时候所指出的那样，Provigo集团是我们提供革命性技术工具的另一个关键步骤，这些工具完全满足了科学家在快速增长的基因组学领域中的科学家的研究需求，”David Harvey说：“David Harvey说，西格玛 - 艾德里奇的主席和首席执行官。"Proligo provides us with one of only four exclusive licenses to a key Massachusetts Institute of Technology patent application that covers the use of RNA in gene silencing, the new frontier in genomics research. It builds on our previously-announced partnership with Ingex, L.L.C. to develop and market their revolutionary new gene disruption technology (TargeTron(TM)); our exclusive licensing arrangement with Rubicon in whole genome amplification (GenomePlex(TM)); our recently announced agreement to serve as a scientific collaborator and distribution partner with The RNAi Consortium, comprised of The Broad Institute, seven world-class research institutions and four commercial partners; and our own internal R&D activities. Collectively, these investments enhance our position in the rapidly growing functional genomics market. We feel that they should permit us to participate as a global leader in the genomics and gene silencing research tools markets for years to come."
ProMigo，总部位于科罗拉多州博尔德，拥有博尔德的制造设施;法国巴黎;汉堡，德国;Helios，新加坡;京都，日本;和澳大利亚的Lismore。该公司在全球约有300名员工。
Sigma-Aldrich资助了短期债务收购。在2005年期间，Sigma-Aldrich预计将在其有针对性的债务中纳入其有针对性债务的资金比率为30％至35％。
http://www.sigma-aldrich.com/